Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	POUR Luděk ADAM Zdeněk BUREŠOVÁ Lucie KREJČÍ Marta KŘIVANOVÁ Andrea SANDECKÁ Viera ZAHRADOVÁ Lenka BÜCHLER Tomáš VORLÍČEK Jiří HÁJEK Roman
Year of publication	2009
Type	Article in Periodical
Magazine / Source	Clinical lymphoma & myeloma
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	Varicella-zoster virus; acyclovir; multiple myeloma
Description	Varicella-zoster virus (VZV) reactivation is a common complication in patients with multiple myeloma (MM) treated with bortezomib, with an incidence rate of 10%-60%. The aim of our study was to analyze the effect of acyclovir prophylaxis in this patient population.
Related projects:	University Research Centre - Czech Myeloma Group From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies